Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated claim—premature discontinuation of dabigatran increases thrombotic risk—is directly supported by the provided FDA labeling text (Boxed Warning and Warnings and Precautions 5.1). No contradictions or unsafe omissions are present for this specific claim.
Category Scores
Accurate Statements
Premature discontinuation increases thrombotic risk.
Supported by Boxed Warning (A) and Warnings and Precautions 5.1, which state that premature discontinuation of any oral anticoagulant including dabigatran increases the risk of thrombotic events.
Unsupported Statements
Contradictions
Important Omissions
The claim evaluation does not explicitly mention the label’s qualifying condition that increased thrombotic risk applies 'in the absence of adequate alternative anticoagulation' (and that pathological bleeding/completion of a course are exceptions).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The core risk statement is label-supported; only a minor omission of the label qualifier/exception condition was noted.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The evaluation statement omits the label’s qualifier about the absence of adequate alternative anticoagulation and the stated exceptions.
Suggested Improvement
Rephrase as 'Premature discontinuation (without adequate alternative anticoagulation) increases the risk of thrombotic events' to mirror Boxed Warning (A) / Warnings and Precautions 5.1 wording.